Skip to content

An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication

An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication According to Instructions Received From Their Physician (AMD).

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00577265
Acronym
INVOLVE
Enrollment
Unknown
Registered
2007-12-20
Start date
2004-11-30
Completion date
Unknown
Last updated
2011-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma Control

Brief summary

An observational study to investigate how patients experience the ability to adjust their asthma maintenance medication according to instructions received from their physician. The primary aim is to create an insight in the perception of the patient when he has the ability to adjust his own maintenance treatment and how the patient exercises this in the daily practice.

Interventions

None listed

Sponsors

AstraZeneca
Lead SponsorINDUSTRY

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Inclusion Criteria: patients with prescription of budesonide/formoterol Turbuhaler 200/6 (adjustable maintenance dosing) and whom received instructions from their physician to adjust their asthma maintenance medication.

Design outcomes

Primary

MeasureTime frame
The primary aim is to create an insight in the perception of the patient when he has the ability to adjust his own maintenance treatment and how the patient exercises this in the daily practice.

Secondary

MeasureTime frame
The secondary goal is to investigate the efficacy of the treatment with budesonide/formoterol AMD on the patients asthma control measured with the ACQ.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026